This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
12 Jul 2013

Routine Generation of Powder Samples from HPLC Fractions

Genevac reports that its HT Series II Evaporator using the Fast Lyophilisation, or LyoSpeed process is enabling a growing number of pharmaceutical labs to routinely dry HPLC fraction samples to a powder form, such that the samples can then be accurately weighed, easily sub-sampled and redissolved.

When working with certain HPLC solvents, such as water and acetonitrile, a fully dried result can be hard to achieve due to interactions with the dissolved sample — esulting in the formation of a gum or oil.

To provide a rapid, high-throughput alternative to freeze drying HPLC purification fractions — Genevac developed its proprietary fast lyophilisation (LyoSpeed) methodology for use on the HT Series II Evaporators. Although LyoSpeed works well for most hydrophilic samples, difficulties may arise where the sample cannot dissolve in only water. In such situations, when the organic solvent is removed, the sample crashes out forming an oil which until now required further processing to achieve the desired dry powder form. For such samples and to improve LyoSpeed results generally — Genevac developed the SuperCool 75 which chills to -75 ºC and operates at higher power than any other commercially available condenser.

Customer trials have shown that the Genevac HT Series II Evaporator/SuperCool 75 combination produces powdered lyophilisation samples using the LyoSpeed methodology from even the most difficult to handle samples with a success rate as high as 95%

For further information please visit www.genevac.com/en/ProductDetail1.asp?S=3&V=1&G=5&Product=12 or contact Genevac now on +44 1473 240 000/+1 845 255 5000 or email [email protected] 
 

Related News

  • News Federal judge blocks Colorado's unprecedented price cap on Amgen's Enbrel

    A US federal court has halted Colorado's attempt to impose a US$31,200 annual price cap on Amgen's arthritis drug Enbrel, ruling that the pharmaceutical company would likely suffer irreparable harm. The decision represents a significant blow to...
  • News Protecting life-saving therapies: CPHI Online Podcast Series

    The latest episode of the CPHI Podcast Series dives into a critical challenge facing the pharmaceutical industry: ensuring the integrity of temperature-sensitive medications and biologics through advanced predictive technology.

  • News 2026 Outsourcing Outlook Update - pharma at a crossroads

    The pharmaceutical contract development and manufacturing organisation (CDMO) sector is experiencing unprecedented transformation, driven by evolving therapeutic complexities, geopolitical tensions, and the growing demand for specialised manufacturing ...
  • News Roche maintains German investment commitment whilst rivals scale back

    Pharmaceutical giant Roche has reaffirmed its commitment to investing in Germany, standing firm even as competitors Eli Lilly and Boehringer Ingelheim dramatically reduce their planned investments in response to controversial healthcare reforms.

  • News Women in Pharma: The History of CPHI Women in Japan

    Our monthly Women in Pharma series highlights the influential lives and work of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive.
  • News EU drafts deal to end essential medicines shortage

    European negotiators have agreed new legislation to tackle persistent shortages of essential medicines by prioritising supply security over price in public procurement and supporting domestic pharmaceutical manufacturing with strategic funding.

  • News Thermo Fisher Scientific offloads microbiology business to PE firm Astorg

    The life sciences giant is divesting its global microbiology unit, which generated $645 million in revenue last year, to the pan-European private equity firm as part of an active portfolio management strategy. The transaction is expected to close in th...
  • News The Shift: Why Sustainability is Moving to the Centre of CPHI Milan 2026

    CPHI Online contributor David Roach takes a look at how conversations around sustainability in the pharmaceutical industry can and must be transformed into actionable deliveries, and what the inaugural CPHI Sustainability Summit means for the industry.